Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MART-1:27-35 peptide vaccine
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A synthetic peptide vaccine consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1 (AAGIGILTV). It's designed to stimulate the host immune system to mount a cytotoxic T-lymphocyte response against melanoma cells expressing the MART-1 antigen. A modified version with a leucine substitution at position 27 (27L) has been developed to improve binding to HLA-A*0201. The vaccine has been studied primarily in patients with high-risk resected stages IIB, III, and IV melanoma.
- Other names
- 27-35(27L):MART-1 peptide vaccine
02
Targets
MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on MART-1:27-35 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MART-1:27-35 peptide vaccine.